Drug intelligence / Profile preview

NK211

Development stage
Phase 2
Lead developer
Nano Holdings
Modality
Small Molecules, Nanoparticles → Drug Delivery Systems
Administration
Intravenous
01

Overview

NK211 is an investigational antineoplastic agent consisting of a polymeric micelle formulation of cisplatin. Developed by Nippon Kayaku in collaboration with NanoCarrier (where it is known as NC-6004), the drug is designed to optimize the delivery of cisplatin to tumor cells. The micellar structure, typically composed of block copolymers like methoxy-polyethylene glycol and poly(glutamic acid), allows for a controlled release of the platinum payload. This formulation aims to exploit the enhanced permeability and retention (EPR) effect to increase intratumoral drug concentrations while minimizing the severe systemic side effects associated with conventional cisplatin, such as nephrotoxicity, ototoxicity, and neurotoxicity. NK211 is currently being evaluated in clinical trials for the treatment of relapsed ovarian cancer.

Brand names
Nanoplatin
Other names
cisplatin micellecisplatin-incorporated polymeric micelle
02

Targets

DNA

Beyond the preview

Go deeper on NK211.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on NK211.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call